showed a trendp = 0.06
After matching, FPDMM‐AML patients again showed a trend toward a favorable outcome, albeit without statistical significance ( p = 0.06) (Figure 5F ).
After matching, FPDMM‐AML patients again showed a trend toward a favorable outcome, albeit without statistical significance ( p = 0.06) (Figure 5F ).
FPDMM‐AML showed an overall trend toward lower frequencies of cytogenetic aberrations in comparison to HOVON RUNX1 ‐mutated AML (Figure 4C ), including monosomal karyotype (0/35, 0% vs. 12/206, 5.8%) and monosomy 5 or 5q deletions (0/35, 0% vs. 12/206, 5.8%).